The most dangerous adverse reaction resulting from sulphonylureas is severe hypoglycemia (in average 2 cases for every 10,000 patients for which there is a mortality of 10%). Glibenclamide and chlorpropamide represent a higher risk of hypoglycemia than other sulphonylureas. Elderly people with reduced renal functions, who take many drugs and have an irregular diet, are particularly endangered. Hematological complications (e.g. thrombocytopenia), cholestatic hepatitis, and general allergic reactions are rare.

Weight gain is common. Gastrointestinal symptoms (nausea, vomiting, dyspepsia) and skin rashes are rare. The FDA insists that sulphonylureas may increase cardiovascular risks. Most likely due to the mild diuretic effect, enuresis has been reported.

Glibenclamide: Interactions

Sulfonamides, beta-blockers, non-steroidal anti-inflammatory agents, etc. hardly increase the risk of hypoglycemia of glibenclamide (on the contrary to many other sulphonylureas).

Table of Contents | Indications | Pharmacology | Contraindications & Cautions | Risk Groups | References